Publications by authors named "Nobuhiro Shibata"

Article Synopsis
  • - The study analyzed how changes in chemotherapy based on CA19-9 levels during neoadjuvant therapy (NAT) impact outcomes for patients with pancreatic ductal adenocarcinoma (PDAC).
  • - Results from 283 patients showed that those who received a chemotherapy change (particularly those who achieved the desired CA19-9 reduction) had significantly better overall survival compared to those who did not have a chemotherapy change.
  • - The findings suggest that adjusting chemotherapy based on CA19-9 levels can enhance treatment outcomes for patients with resectable or borderline resectable PDAC, highlighting the importance of personalized treatment approaches.
View Article and Find Full Text PDF

We provide updated results (median follow-up duration: 20.4 months) of a retrospective study on the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer with brain metastases (BM) and/or leptomeningeal disease (ROSET-BM). Median progression-free survival (PFS) was 14.

View Article and Find Full Text PDF
Article Synopsis
  • This study evaluated the effects of preoperative endoscopic ultrasound-guided tissue acquisition (EUS-TA) on patients with resectable or borderline resectable pancreatic cancer.
  • Data from 153 patients showed no significant differences in overall survival or positive peritoneal lavage cytology between those who underwent EUS-TA and those who did not.
  • The findings suggest that EUS-TA does not negatively affect postoperative survival or the rates of positive cytology in pancreatic cancer surgeries.
View Article and Find Full Text PDF
Article Synopsis
  • The study evaluates the effectiveness of conversion surgery for patients with liver-only synchronous metastases of pancreatic ductal adenocarcinoma who responded positively to chemotherapy, comparing outcomes with other treatment methods.
  • A total of 49 patients were analyzed, divided into three groups: those who had conversion surgery (10), upfront surgery (8), and those who only received chemotherapy (31).
  • Results showed that the conversion surgery group had significantly better median survival times (36.7 months) compared to the chemotherapy group (9.9 months) and the upfront surgery group (10.4 months), highlighting the potential benefit of conversion surgery for selected patients.
View Article and Find Full Text PDF
Article Synopsis
  • Therapeutic options are limited for breast cancer patients with brain metastases (BM) and leptomeningeal carcinomatosis (LMC), but trastuzumab deruxtecan (T-DXd) shows promise.
  • In a study of 104 HER2-positive breast cancer patients treated with T-DXd, the overall response rate (ORR) was 55.7%, with median progression-free survival (PFS) of 16.1 months.
  • For patients with BM, intracranial ORR was 62.7%, while in those with LMC, 12-month PFS and overall survival (OS) rates were 60.7% and 87.1%, indicating effective disease control.
View Article and Find Full Text PDF

In recent years, both the number of patients with breast cancer and those with associated brain metastases (BMs) have increased. Human epidermal growth factor receptor 2 (HER2)-positive breast cancer has a high BM frequency. The prognosis of BM from breast cancer is poor, and establishing effective treatment for this disease is essential.

View Article and Find Full Text PDF

Purpose: This study aimed to describe perioperative chemotherapy patterns, granulocyte colony-stimulating factor (G-CSF) use, and febrile neutropenia (FN) status in patients with early breast cancer (EBC) using real-world data in Japan.

Methods: This retrospective observational study used anonymized claims data. The included patients were ≥ 18 years old, were female, and had breast cancer diagnosis and surgery records between January 2010 and April 2020.

View Article and Find Full Text PDF

Although nanoliposomal irinotecan combined with 5-fluorouracil and leucovorin (nal-IRI+5-FU/LV) has been used to treat first-line resistant unresectable pancreatic cancer, the efficacy and safety data among the elderly remain limited. We retrospectively analyzed clinical outcomes among elderly patients. Patients treated with nal-IRI+5-FU/LV were assigned to the elderly (≥75 years) and non-elderly (<75 years) groups.

View Article and Find Full Text PDF
Article Synopsis
  • The study compares the characteristics and survival outcomes of pancreatic ductal adenocarcinoma (PDAC) patients with occult metastases (OM) to those with radiologically defined metastases (RM).
  • Findings show that patients with OM had better overall survival (13.0 months) compared to those with RM (8.9 months), despite both groups experiencing severe disease.
  • Factors such as overall health status, tumor size, and treatment strategies were identified as key independent predictors of survival, with the type of metastasis (OM vs. RM) not being a significant factor.
View Article and Find Full Text PDF

Background: A trial with trifluridine/tipiracil (FTD/TPI) versus placebo in patients with heavily pretreated metastatic gastric cancer showed that FTD/TPI is effective with manageable toxicity in these patients. However, real-world data on the effects of FTD/TPI in patients with advanced gastric cancer (AGC) are limited.

Methods: We retrospectively collected and analyzed the clinicopathological data of patients with AGC who received FTD/TPI monotherapy at our institutions (Kobe City Medical Center General Hospital, Osaka Red Cross Hospital, Himeji Red Cross Hospital, and Kansai Medical University Hospital) between September 2019 and July 2021.

View Article and Find Full Text PDF
Article Synopsis
  • Nivolumab is the standard treatment in Japan for patients with advanced esophageal squamous cell carcinoma (ESCC) who can't tolerate traditional chemotherapy.
  • A study analyzed clinical data of 93 patients treated with nivolumab to assess inflammatory prognostic factors like CAR (C-reactive protein/albumin ratio) and their impact on survival.
  • Results showed that patients with a CAR value below 0.62 had significantly longer overall survival, indicating that CAR is a useful predictor of prognosis in these patients.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates treatment strategies for patients with multifocal intraductal papillary mucinous neoplasms (MF-IPMNs) and how their surgical outcomes compare to those with unifocal IPMNs.
  • A total of 194 patients were analyzed, finding no significant differences in 5-year disease-specific survival rates between those with MF-IPMNs and unifocal IPMNs.
  • The research concluded that each cyst in MF-IPMNs should be individually assessed for cancer-related characteristics, highlighting lymph node metastasis as a key survival predictor.
View Article and Find Full Text PDF
Article Synopsis
  • Trastuzumab deruxtecan (T-DXd) demonstrates effectiveness in treating advanced gastric cancer (AGC), but real-world efficacy and predictive markers are not fully understood.
  • A study analyzed data from 18 AGC patients who had previously failed multiple treatments, revealing a 41% overall response rate and a median overall survival of 6.1 months.
  • Key factors associated with better outcomes included prior treatment with immune checkpoint inhibitors (ICIs) and having a trastuzumab-free interval of at least 8 months, while patients with ascites had poorer survival rates.
View Article and Find Full Text PDF

Background/aim: Pancreatic ductal adenocarcinoma (PDAC) is one of the most common cancers worldwide, with a poor prognosis. Owing to the difficulty of early diagnosis, the aim of this study was to isolate biomarkers from extracellular vesicles (EVs) that can lead to early diagnosis.

Materials And Methods: EVs in the culture supernatant were isolated from a pancreatic cancer cell line (PK-1) and expanded by using two-dimensional gel electrophoresis, and protein identification from each spot was performed by using matrix-assisted laser desorption ionization mass spectrometry.

View Article and Find Full Text PDF
Article Synopsis
  • Intraperitoneal chemotherapy with paclitaxel (i.p.-PTX) shows promise as a treatment for pancreatic ductal adenocarcinoma (PDAC) with peritoneal dissemination, potentially improving patient outcomes.
  • A study of 101 patients found that those treated with i.p.-PTX had a median survival time of 17.9 months, significantly longer than the 10.2 months for those receiving standard systemic chemotherapy.
  • Additionally, patients receiving i.p.-PTX had a higher rate of clinical responses and were more likely to undergo successful conversion surgeries, indicating better overall treatment efficacy.
View Article and Find Full Text PDF

Medication support applications(apps)have been introduced to support oral anti-cancer drug management for outpatients with gastrointestinal cancer. It has been suggested that remote support using medication support apps contributes to improving the quality of life through adverse event management as well as medication management. However, it was evident that elderly patients could not install the apps due to barriers related to the network environments and device operations and medical problems such as information management and securing human resources.

View Article and Find Full Text PDF

Preoperative chemotherapy is efficacious in several cancers. However, it is not an established treatment for locally advanced colon cancer, particularly cases with microsatellite instability-high (MSI-H)/deficient mismatch repair. Herein, we report a case of pathological complete response of MSI-H clinical T4b ascending colon cancer to preoperative treatment with pembrolizumab.

View Article and Find Full Text PDF
Article Synopsis
  • RAS/BRAF mutations, significant in colorectal cancer (CRC) treatment decisions, were studied in a group of 152 chemotherapy-naïve metastatic CRC patients in Japan, revealing a 54% mutation rate.
  • Distinct mutation patterns were found: BRAF mutations mostly in the right colon, while KRAS non-Exon2 and NRAS mutations were more common in the left colon.
  • Patients with KRAS non-Exon2 and NRAS mutations had shorter survival rates compared to those with wild-type RAS strains and KRAS Exon2 mutations, indicating significant prognostic implications.
View Article and Find Full Text PDF

Summary: A 54-year-old woman was referred to our hospital with a cervical tumor. CT revealed a cervical tumor extending to the upper mediastinum, tracheal deviation and tumor infiltration in the cervical vessels. She was followed-up because no diagnosis of malignancy was made by cytology.

View Article and Find Full Text PDF

We report a case of rapid pleural effusion after discontinuation of lenvatinib. A 73-year-old woman was diagnosed with poorly differentiated thyroid cancer with right pleural metastasis. Weekly paclitaxel treatment was performed for 18 weeks, but it was not effective.

View Article and Find Full Text PDF

A 59-year-old man was admitted to our hospital for the treatment of gastric cancer with synchronous and multiple metastatic liver tumors. After total gastrectomy in February 2005, partial resection of the posterior segment of the liver was carried out in the next month. Pathological study of both the resected specimens showed moderately differentiated adenocarcinoma.

View Article and Find Full Text PDF

Purpose: It is widely accepted that antimicrobial prophylaxis is useful for the prevention of surgical wound infection, especially in colorectal surgery. While many reports support the finding that the first dose should be administered immediately before surgery, there is less evidence concerning the ideal timing for the second dose. The purpose of this study is to examine the significance of intraoperative repeated dosing.

View Article and Find Full Text PDF